The Food and Drug Administration of the Philippines (PFDA) is seeking comments on a draft circular that establishes stricter requirements for medical device safety and traceability.
Scope of the Circular
The guidelines apply to all registered medical devices and IVDs in the Philippines. The scope covers all manufacturers, traders, distributors (importers/exporters/wholesalers), retailers, and dealers. It aims to strengthen post-market surveillance (PMS) obligations by providing structured and enforceable requirements for:
- Importation and distribution record-keeping
- Product complaint handling and reporting
- Adverse Event (AE) reporting
- Field Safety Corrective Action (FSCA) reporting
Stakeholder Responsibilities and Obligations
1. Marketing Authorization Holders (MAHs)
- The MAH is responsible and accountable for the safety, efficacy, and quality of health products in the market.
- MAHs must establish and maintain systems to receive, document, evaluate, and investigate complaints, AEs, and FSCAs.
- They must evaluate all complaints and be accountable to determine whether complaints are reportable and whether they qualify as AEs.
- They must notify PFDA of reportable incidents in compliance with specified timelines.
2. Dealers (manufacturers, traders, distributors (importers/exporters/wholesalers), retailers)
- Dealers must ensure records enable tracing from point of entry to point of distribution.
- Dealers who receive product complaints or become aware of an AE must forward relevant information to MAHs within fourteen (14) calendar days.
- Cooperate with MAHs and PFDA during investigations and follow-up actions.
Timelines for Reporting Events
The draft requires strict timelines for reporting issues to FDA CDRRHR that may affect patient safety:
A. AE Reporting Timelines
| Type of Adverse Event | Reporting Deadline |
| Serious threat to public health | Within 48 hours |
| Death or serious deterioration in health | Within 10 days |
| Potential to cause death or serious deterioration if it recurs | Within 30 calendar days |
B. FSCA Reporting Timelines
FSCA reporting is based on the level of risk and aligned with AE reporting timelines. The draft circular specifies a fixed timeline for FSCA. The MAH must submit the FSCA Report Form within fourteen (14) calendar days from the date of initiation of the local FSCA or the date of receipt of the manufacturer's official global communication, whichever occurs first.
Note: Reports should be transmitted to PFDA via designated channels/contacts established under the draft.
Traceability and Record Retention
The draft requires maintenance of records to support traceability:
- Importation records to track devices entering the country
- Distribution records to track movement of devices
Records must contain sufficient details, including lot, batch, or serial numbers, to enable a swift and complete market withdrawal if necessary.
The draft provides specific retention periods to ensure traceability, auditability, and regulatory compliance:
| Record Type | Retention Timeline |
| Product complaint records (including investigation and corrective actions) | Five (5) years beyond the projected useful life or shelf life of the medical device |
| Importation and distribution records | Whichever is longer: (i) the projected useful (service) life or shelf life of the medical device; (ii) two (2) years after the date the device is supplied; or (iii) for devices imported solely for export, two (2) years after the date of shipment out of the Philippines |
Labeling Non-Compliance and Warning Letters
The draft also states that PFDA may conduct product verification to ensure actual labels match approved versions. If discrepancies are found:
- The FDA will issue a Warning Letter to the MAH.
- The MAH must submit an FSCA Report Form within fourteen (14) calendar days from acknowledgment of the letter.
- The proposed corrective action timeline must not exceed sixty (60) calendar days.
Transitory Provision
All MAHs will be granted a six (6) month transition period from the effectivity date of the circular to ensure full compliance with these new requirements.
Key Take Away
This draft guideline emphasizes a structured system for traceability, reporting, and corrective actions. It strengthens the regulatory framework to ensure that medical devices in the Philippine market remain safe, effective, and of quality throughout their lifecycle.
Key Actions for Stakeholders to Ensure Compliance
Medical device manufacturers, MAHs, importers, distributors, and risk managers should:
- ✔ Review and update internal SOPs to align with this draft
- ✔ Strengthen complaint handling and evaluation procedures
- ✔ Maintain accurate and complete records
- ✔ Ensure awareness of reporting timelines
- ✔ Prepare procedures for handling corrective actions
- ✔ Align internal processes with ASEAN PMS expectations
Qualtech Consulting Corporation has been a trusted partner for medical device manufacturers for over 26 years. Whether you're a local startup or an international player, we empower your devices to enhance lives.
Connect with us today here to unlock your medical device potential!
Reference